Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities?

Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. The subjects were 50 advanced gastric cancer pa...

Full description

Saved in:
Bibliographic Details
Published inJapanese journal of clinical oncology Vol. 31; no. 8; pp. 382 - 387
Main Author Boku, N.
Format Journal Article
LanguageEnglish
Published England Oxford Publishing Limited (England) 01.08.2001
Subjects
Online AccessGet full text
ISSN1465-3621
0368-2811
1465-3621
DOI10.1093/jjco/hye085

Cover

Abstract Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed. The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia. Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.
AbstractList Background: Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. Methods: The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed. Results: The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir (> or = or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia. Conclusion: Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.
Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance.BACKGROUNDSome anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance.The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed.METHODSThe subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed.The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia.RESULTSThe serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia.Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.CONCLUSIONHyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.
Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with 5-fluorouracil and cisplatin (FP) was investigated retrospectively to clarify its clinical significance. The subjects were 50 advanced gastric cancer patients treated with FP. Patients' performance status, oral intake, nausea/vomiting, diarrhea, fever, urine volume, presence of ascites or pleural effusion, laboratory data and administration of diuretics, corticosteroid and contents and volume of hydration before and during the first 5 days after chemotherapy were reviewed. The serum sodium level decreased after initiation of chemotherapy in all patients and the lowest level (nadir) was most frequently observed on day 8 (range, days 2-14), which preceded hematological toxicities. In 10 patients (20%) the nadir of serum sodium was lower than 125 mEq/l. We classified these 10 patients as a low-sodium group and the others into a normal-sodium group. Six (60%) and seven (70%) of the 10 patients in the low-sodium group had complications with grade 3 or 4 leukopenia and thrombocytopenia, whereas only one (3%) and two (5%) were seen in the normal-sodium group (p < 0.0001). Stomatitis and diarrhea were also slightly more severe in the former than the latter group. With respect to sensitivity and probability, receiver operating characteristic curves showed the nadir ((> or = ) or <125 mEq/l) of the serum sodium level was the best marker for both leukopenia and thrombocytopenia. Hyponatremia after initiation of chemotherapy with FP may be a warning sign of subsequent severe hematological toxicity.
Author Boku, N.
Author_xml – sequence: 1
  givenname: N.
  surname: Boku
  fullname: Boku, N.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11574631$$D View this record in MEDLINE/PubMed
BookMark eNptkU1v1DAQhiNURD_gxB1ZHLigUDuJ88EFoajtIlWiYhdxtCbOZNcrx05tp3R_H38Mb7cgVHGakeZ5X83Me5ocGWswSV4z-oHRJj_fbqU93-yQ1vxZcsKKkqd5mbGjf_rj5NT7LaWU10X1IjlmjFdFmbOT5Nc3DM76CWVQd0iWYe53xA5ksZusgeBwVECUIVfgg1OStGAkOnIDQaEJnqwcQsCe_FRhQ4C0duxU1ClrSLvB0YYNOpgeLHl6qWfr7OxAKk3A9KRVftKRNh-j9sZ6rzqN5Ac4o8yaLNXa7IVLvEOHZIEjBKvtWknQZGXvlVRxC__pZfJ8AO3x1WM9S75fXqzaRXr99epL-_k6lXlehlTKpuu6oc9qlvXQZHkpeQG0AhrnwIuiR5k3kiOvZTFI3pV1CZgNsTZZL7v8LHl38J2cvZ3RBzEqL1FrMGhnLyqWUZrVdQTfPgG38WoTdxMZqxjNS95E6M0jNHcj9mJyagS3E3-yiQA7ADIG5B0OIt778NrgQGnBqNjnL_b5i0P-UfP-ieav7X_o32nRt78
CitedBy_id crossref_primary_10_1007_s10388_018_0615_y
crossref_primary_10_1080_21645515_2024_2414546
crossref_primary_10_1111_cas_12486
crossref_primary_10_1007_s00520_007_0309_9
crossref_primary_10_5981_jjhnc_40_38
crossref_primary_10_1111_ecc_12187
ContentType Journal Article
Copyright Copyright Oxford University Press(England) Aug 1, 2001
Copyright_xml – notice: Copyright Oxford University Press(England) Aug 1, 2001
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7T7
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
P64
7X8
DOI 10.1093/jjco/hye085
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Oncogenes and Growth Factors Abstracts
Technology Research Database
Nucleic Acids Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Immunology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1465-3621
EndPage 387
ExternalDocumentID 376839061
11574631
10_1093_jjco_hye085
Genre Journal Article
GroupedDBID ---
-E4
.2P
.55
.I3
.ZR
0R~
18M
1TH
29J
2WC
3O-
4.4
482
48X
5GY
5RE
5VS
5WA
5WD
7.U
70D
AABZA
AACZT
AAJKP
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNGD
ABNHQ
ABNKS
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUKT
ACUTO
ACYHN
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFRAH
AFXAL
AGINJ
AGKEF
AGORE
AGQPQ
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ASPBG
ATGXG
AVWKF
AXUDD
AZFZN
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CAG
CDBKE
CITATION
COF
CS3
CZ4
DAKXR
DIK
DILTD
DU5
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FEDTE
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H5~
HAR
HVGLF
HW0
HZ~
IH2
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
M-Z
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NTWIH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PB-
PEELM
PQQKQ
Q1.
Q5Y
RD5
RNI
ROX
ROZ
RUSNO
RW1
RXO
RZF
RZO
TCURE
TEORI
TJX
TKC
TR2
UDS
W8F
WOQ
X7H
X7M
YAYTL
YKOAZ
YXANX
ZKX
~91
.GJ
53G
6.Y
AAJQQ
AAPGJ
AAWDT
ABQTQ
ABSAR
ABSMQ
ACFRR
ACPQN
ACUTJ
ACZBC
ADJQC
ADRIX
AEHUL
AEKPW
AFFQV
AFSHK
AFXEN
AFYAG
AGKRT
AGMDO
APJGH
AQDSO
AQKUS
ATTQO
BZKNY
CGR
CUY
CVF
ECM
EIF
EIHJH
H13
M49
MBLQV
NPM
O~Y
QBD
R44
RHF
TMA
X7J
ZGI
7T5
7T7
7TM
7TO
7U9
8FD
C1K
FR3
H94
K9.
P64
7X8
ID FETCH-LOGICAL-c336t-cc9bbbfd2812da9236c54a07a0c33a544dec39c5e58c4fc5b686ae2fb6892dcb3
ISSN 1465-3621
0368-2811
IngestDate Fri Jul 11 16:14:55 EDT 2025
Mon Jun 30 16:58:05 EDT 2025
Wed Feb 19 02:33:33 EST 2025
Tue Jul 01 04:34:53 EDT 2025
Thu Apr 24 23:08:01 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 8
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c336t-cc9bbbfd2812da9236c54a07a0c33a544dec39c5e58c4fc5b686ae2fb6892dcb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
content type line 23
PMID 11574631
PQID 217103659
PQPubID 46566
PageCount 6
ParticipantIDs proquest_miscellaneous_71200288
proquest_journals_217103659
pubmed_primary_11574631
crossref_citationtrail_10_1093_jjco_hye085
crossref_primary_10_1093_jjco_hye085
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2001-08-01
PublicationDateYYYYMMDD 2001-08-01
PublicationDate_xml – month: 08
  year: 2001
  text: 2001-08-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle Japanese journal of clinical oncology
PublicationTitleAlternate Jpn J Clin Oncol
PublicationYear 2001
Publisher Oxford Publishing Limited (England)
Publisher_xml – name: Oxford Publishing Limited (England)
SSID ssj0005847
Score 1.6279509
Snippet Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with...
Background: Some anti-neoplastic agents induce hyponatremia. The relationship between hyponatremia and other toxicities in gastric cancer patients treated with...
SourceID proquest
pubmed
crossref
SourceType Aggregation Database
Index Database
Enrichment Source
StartPage 382
SubjectTerms Antineoplastic Combined Chemotherapy Protocols - adverse effects
Cisplatin - adverse effects
Drug Resistance, Neoplasm
Female
Fluorouracil - adverse effects
Humans
Hyponatremia - chemically induced
Leukopenia - chemically induced
Male
Middle Aged
Retrospective Studies
ROC Curve
Sodium - blood
Stomach Neoplasms - drug therapy
Thrombocytopenia - chemically induced
Title Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities?
URI https://www.ncbi.nlm.nih.gov/pubmed/11574631
https://www.proquest.com/docview/217103659
https://www.proquest.com/docview/71200288
Volume 31
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaWIiEuqDy7LQ8feqIKTeI8uSBYUZaiIgRb0VvkOLZIWZLVbiJR_hQ_gj_GTOxkk7JIhUsSORlvNvN5ZmzPg5B9zFFuZ0FgKcfJLI8rz4ojN7aUGyrm4kYfxwX9k_fB9NQ7PvPPRqOfPa-lukqfiR8b40r-h6vQBnzFKNl_4GzXKTTANfAXjsBhOF6Jxx9ltSzbWMnGJbDZL59eLHBNfCm_5RzXM95wLM4hDibI4SVm5c-buLYZGoyt-zlH0QDTZA0IzCNgYrOaLn3raF6XS3gpLnKdXWCSrxboSFfoeOkPJY6uuTz4bNZaPmHFTwyJkfBdJeg3sI07STsrv-eiSeZ6ybPwGJQ3FsXsp7ToojfLQgx2AV6VX2sdLjZYvHA617lW3nqBb4EO1U1yQ5sR0szpgTHqSVymaxcZ5c209v5DL-icWefnooTTlwtp6zpBw_zbl_Ri562o9-lZguSJJr5GrrthqP0C3r5b-xRFTUW77h-YgFAgPkTiQ008NIH-Mq9p7JvZNrllJib0pUbZbTKSxR1y48S4XtwlvwZgow3YaKloH2w0L6gBG9Vgoy3YqAEbRbBRTntgo32wYZdDsFEAG-3A9hxoW6hRAzWKUENCDTU6gBpdQ-3FPXJ69Ho2mVqmAoglGAsqS4g4TVOVuWCGZhzmIoHwPW6H3Ib73Pe8TAoWC1_6kfCU8NMgCrh0FZxjNxMpu0-2irKQO4QqMNdkJmKbha6HVQkc7qgoCyOuhBS2PSZPW6YkwqTHxyot82QD-8dkv3t4obPCbH5sr-VuYkbNKnEdMOpZ4Mdj8qS7CzIdN-pggJX1KgkddJ2KojF5oCGx_hHHD72AObtXe4E9cnM96h6SrWpZy0dgRFfp4wa4vwFWCNS6
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retrospective+Study+of+Hyponatremia+in+Gastric+Cancer+Patients+Treated+with+a+Combination+Chemotherapy+of+5-Fluorouracil+and+Cisplatin%3A+a+Possible+Warning+Sign+of+Severe+Hematological+Toxicities%3F&rft.jtitle=Japanese+journal+of+clinical+oncology&rft.au=Boku%2C+N.&rft.date=2001-08-01&rft.issn=1465-3621&rft.eissn=1465-3621&rft.volume=31&rft.issue=8&rft.spage=382&rft.epage=387&rft_id=info:doi/10.1093%2Fjjco%2Fhye085&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_jjco_hye085
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-3621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-3621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-3621&client=summon